Can-Fite Biopharma shares rise 10.46% intraday after receiving patent allowance for Cf602 erectile dysfunction treatment in Brazil.

Can-Fite Biopharma surged 10.46% intraday after announcing that its Cf602 erectile dysfunction treatment received a Notice of Patent Allowance in Brazil. The patent, a key milestone for the drug’s commercialization potential in the region, signals regulatory progress and exclusivity, likely bolstering investor confidence. The news aligns with the stock’s upward trajectory, as patent approvals often enhance market positioning for biotech firms. Other details in the news, such as pipeline updates and licensing deals, were not directly linked to the intraday price movement.